NEW YORK (GenomeWeb News) – Illumina reported after the close of the market Monday that its fourth-quarter revenues climbed 24 percent, topping analysts' consensus estimate.

The San Diego-based genetic analysis products firm brought in total revenues of $309.3 million for the three months ended Dec. 30, 2012, in line with its pre-announcement and up from $250.1 million for the fourth quarter of 2011. It beat the consensus Wall Street estimate of $305.4 million.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

The president of France's National Research Agency has resigned, according to Nature News.

A senator wants a "right-to-try" provision in the US Food and Drug Administration funding bill, but an ethicist says at Stat News that it would undermine the role of clinical trials.

In PNAS this week: red algae Porphyra umbicalis genome, deep neural network model for sequencing peptides, and more.

The Guardian's Barbara Ellen has tried out some DNA testing services to see whether they provide valuable information.